NASDAQ:ALVR AlloVir (ALVR) Stock Price, News & Analysis $6.27 -0.63 (-9.13%) As of 04/30/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About AlloVir Stock (NASDAQ:ALVR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AlloVir alerts:Sign Up Key Stats Today's Range$6.26▼$7.0050-Day Range$6.46▼$11.4752-Week Range$7.96▼$24.15Volume24,807 shsAverage Volume16,152 shsMarket Capitalization$31.62 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.Read More… Receive ALVR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AlloVir and its competitors with MarketBeat's FREE daily newsletter. Email Address ALVR Stock News HeadlinesKalaris Announces Closing of Merger with AlloVirMarch 18, 2025 | globenewswire.comAlloVir shareholders approve merger with Kalaris TherapeuticsMarch 14, 2025 | investing.comThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang said, "The ChatGPT moment for robotics is right around the corner." In fact, I believe these robots could impact 65 million Americans lives — this year. And one stock — currently priced around $7 — could be the biggest winner.May 1, 2025 | Weiss Ratings (Ad)AlloVir, Inc.: Kalaris and AlloVir Announce Stockholder Approval of MergerMarch 13, 2025 | finanznachrichten.deKalaris, AlloVir announce stockholder approval of mergerMarch 13, 2025 | markets.businessinsider.comKalaris and AlloVir Announce Stockholder Approval of MergerMarch 12, 2025 | globenewswire.comAlloVir, Inc. (ALVR) Latest Press Releases & Corporate News - Yahoo FinanceMarch 4, 2025 | finance.yahoo.comAllovir's Vikas Sinha sells shares worth $3,052February 26, 2025 | investing.comSee More Headlines ALVR Stock Analysis - Frequently Asked Questions How have ALVR shares performed this year? AlloVir's stock was trading at $9.66 at the beginning of 2025. Since then, ALVR stock has decreased by 35.1% and is now trading at $6.27. View the best growth stocks for 2025 here. How were AlloVir's earnings last quarter? AlloVir, Inc. (NASDAQ:ALVR) issued its quarterly earnings data on Wednesday, August, 14th. The company reported ($1.15) EPS for the quarter, topping analysts' consensus estimates of ($2.30) by $1.15. When did AlloVir's stock split? Shares of AlloVir reverse split before market open on Thursday, January 16th 2025. The 1-23 reverse split was announced on Wednesday, January 15th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, January 15th 2025. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did AlloVir IPO? AlloVir (ALVR) raised $252 million in an IPO on Thursday, July 30th 2020. The company issued 14,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler acted as the underwriters for the IPO. How do I buy shares of AlloVir? Shares of ALVR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AlloVir own? Based on aggregate information from My MarketBeat watchlists, some other companies that AlloVir investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AUO (AUOTY), DiamondRock Hospitality (DRH) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/14/2024Today5/01/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALVR CIK1754068 Webwww.allovir.com Phone617-433-2605FaxN/AEmployees110Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($20.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-190,420,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-71.03% Return on Assets-61.27% Debt Debt-to-Equity RatioN/A Current Ratio86.78 Quick Ratio86.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$29.35 per share Price / Book0.24Miscellaneous Outstanding Shares5,043,000Free Float3,425,000Market Cap$34.80 million OptionableOptionable Beta0.63 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (NASDAQ:ALVR) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AlloVir, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AlloVir With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.